Physicians who practiced medicine 25 years ago likely remember the use of high-dose intravenous steroids, such as 1-g boluses of methylprednisolone, for septic shock. The practice was fueled by anecdotes of miraculous recoveries, but large randomized trials failed to demonstrate benefit and raised the specter of possible harm. Steroids were abandoned and lay dormant for years, until recent studies suggested that septic shock may be exacerbated by relative adrenal insufficiency and that smaller dose of steroids for longer periods of time may be beneficial. In 2002, in a multicenter French study, Annane et al1 reported lower mortality among patients in septic shock who were randomized to a 1-week course of low-dose steroids. This study ignited such rapid interest in steroids that the United States temporarily ran out of hydrocortisone. For those who lament the usually slow adoption of evidence into clinical practice, this event was a marked departure from the norm. Subsequent meta-analyses, systematic reviews, and professional society guidelines all echoed the notion that vasopressor-dependent septic shock should be treated with corticosteroids.
Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more
Subscribe for full-text access to content from 1998 forward and a host of useful features
Activate your current subscription (AMA members and current subscribers)
Purchase Online Access to this article for 24 hours
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 8
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
and access these and other features:
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.